Extension to a Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes

Extension to a Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes

This is a 28-week extension to a study of the safety and effectiveness of three doses of vildagliptin, an unapproved drug, compared to placebo in lowering overall blood glucose levels in people with type 2 diabetes who have not been previously treated with drug therapy to lower their blood sugar. The purpose of the extension study is to gather long-term safety and efficacy data for vildagliptin in people with type 2 diabetes.

Inclusion Criteria:

• Only patients successfully completing study CLAF237A2301 are eligible
• Written informed consent
• Ability to comply with all study requirements

Exclusion Criteria:

• Premature discontinuation from study CLAF237A2301
• Other protocol-defined exclusion criteria may apply